In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was $6.75 for the day, down -4.80% from the previous closing price of $7.09. In other words, the price has decreased by -$4.80 from its previous closing price. On the day, 6.43 million shares were traded. BCRX stock price reached its highest trading level at $7.13 during the session, while it also had its lowest trading level at $6.69.
Ratios:
Our analysis of BCRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.86. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.87.
On October 01, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 22 ’25 when Barnes Alane P sold 21,773 shares for $7.65 per share. The transaction valued at 166,563 led to the insider holds 398,751 shares of the business.
Barnes Alane P bought 21,773 shares of BCRX for $166,563 on Dec 22 ’25. On Dec 15 ’25, another insider, Barnes Alane P, who serves as the Chief Legal Officer of the company, sold 21,210 shares for $7.65 each. As a result, the insider received 162,256 and left with 315,726 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1422488576 and an Enterprise Value of 1891402752. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.37. Its current Enterprise Value per Revenue stands at 3.153 whereas that against EBITDA is 23.516.
Stock Price History:
The Beta on a monthly basis for BCRX is 0.82, which has changed by -0.019363761 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is -7.85%, while the 200-Day Moving Average is calculated to be -18.06%.
Shares Statistics:
BCRX traded an average of 5.17M shares per day over the past three months and 4204250 shares per day over the past ten days. A total of 210.52M shares are outstanding, with a floating share count of 193.68M. Insiders hold about 8.10% of the company’s shares, while institutions hold 93.84% stake in the company. Shares short for BCRX as of 1767139200 were 39061667 with a Short Ratio of 7.55, compared to 1764288000 on 37382162. Therefore, it implies a Short% of Shares Outstanding of 39061667 and a Short% of Float of 18.61.
Earnings Estimates
The market rating for Biocryst Pharmaceuticals Inc (BCRX) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.12, with high estimates of $0.13 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.5 and $0.45 for the fiscal current year, implying an average EPS of $0.47. EPS for the following year is $0.46, with 3.0 analysts recommending between $0.7 and $0.05.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $157.72M to a low estimate of $145.45M. As of. The current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $131.53MFor the next quarter, 8 analysts are estimating revenue of $152.04M. There is a high estimate of $156.34M for the next quarter, whereas the lowest estimate is $149.21M.
A total of 8 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $626M, while the lowest revenue estimate was $613.73M, resulting in an average revenue estimate of $618.94M. In the same quarter a year ago, actual revenue was $450.71MBased on 8 analysts’ estimates, the company’s revenue will be $662.46M in the next fiscal year. The high estimate is $685M and the low estimate is $648.5M.
